Total Payments
$72,984
2024 Payments
$24.50
Companies
14
Transactions
135
Medicare Patients
14,973
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$52,600 (72.1%)
Travel$11,033 (15.1%)
Consulting$7,200 (9.9%)
Food & Beverage$2,122 (2.9%)
Education$29.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $52,600 | 41 | 72.1% |
| Travel and Lodging | $11,033 | 35 | 15.1% |
| Consulting Fee | $7,200 | 5 | 9.9% |
| Food and Beverage | $2,122 | 47 | 2.9% |
| Education | $29.24 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lundbeck LLC | $71,597 | 112 | $0 (2020) |
| BAXTER HEALTHCARE | $900.00 | 3 | $0 (2020) |
| Boston Scientific Corporation | $141.51 | 2 | $0 (2019) |
| Bard Peripheral Vascular, Inc. | $134.85 | 1 | $0 (2020) |
| Relypsa, Inc. | $79.39 | 4 | $0 (2020) |
| Amgen Inc. | $24.50 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $17.14 | 1 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $16.53 | 1 | $0 (2019) |
| Novo Nordisk Inc | $15.87 | 1 | $0 (2017) |
| Lilly USA, LLC | $15.56 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24.50 | 1 | Amgen Inc. ($24.50) |
| 2023 | $13.60 | 1 | Calliditas Therapeutics US Inc. ($13.60) |
| 2022 | $16.33 | 2 | Horizon Therapeutics plc ($12.51) |
| 2021 | $7.64 | 2 | Travere Therapeutics, Inc. ($7.64) |
| 2020 | $2,050 | 6 | Lundbeck LLC ($1,596) |
| 2019 | $6,337 | 17 | Lundbeck LLC ($5,659) |
| 2018 | $18,783 | 28 | Lundbeck LLC ($18,658) |
| 2017 | $45,752 | 78 | Lundbeck LLC ($45,685) |
All Payment Transactions
135 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/29/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Education | Cash or cash equivalent | $13.60 | General |
| Category: Nephrology | ||||||
| 02/26/2022 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $12.51 | General |
| Category: KRYSTEXXA | ||||||
| 02/10/2022 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 10/12/2021 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 02/03/2021 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 11/10/2020 | Lundbeck LLC | NORTHERA (Drug) | Honoraria | Cash or cash equivalent | $525.00 | General |
| Category: NEUROLOGY | ||||||
| 06/15/2020 | BAXTER HEALTHCARE | Fluid Systems - Research Devel (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Fluid Systems | ||||||
| 04/04/2020 | Lundbeck LLC | NORTHERA (Drug) | Honoraria | Cash or cash equivalent | $1,050.00 | General |
| Category: NEUROLOGY | ||||||
| 02/11/2020 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Hyperkalemia | ||||||
| 01/23/2020 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $21.49 | General |
| Category: NEUROLOGY | ||||||
| 01/06/2020 | Bard Peripheral Vascular, Inc. | — | Food and Beverage | In-kind items and services | $134.85 | General |
| Category: BD Interventional - Peripheral Intervention | ||||||
| 10/22/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Hyperkalemia | ||||||
| 09/20/2019 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Immunology | ||||||
| 09/05/2019 | Lundbeck LLC | NORTHERA (Drug) | Honoraria | Cash or cash equivalent | $1,600.00 | General |
| Category: NEUROLOGY | ||||||
| 08/22/2019 | BAXTER HEALTHCARE | Renal - Non Product Related (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Renal | ||||||
| 08/12/2019 | Lundbeck LLC | NORTHERA (Drug) | Food and Beverage | Cash or cash equivalent | $17.70 | General |
| Category: NEUROLOGY | ||||||
| 08/07/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: NEPHROLOGY | ||||||
| 07/23/2019 | BAXTER HEALTHCARE | BioPharma Sol - Research Devel (Biological) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: BioPharma Solutions | ||||||
| 06/12/2019 | Lundbeck LLC | NORTHERA (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 06/06/2019 | Lundbeck LLC | NORTHERA (Drug) | Honoraria | Cash or cash equivalent | $875.00 | General |
| Category: NEUROLOGY | ||||||
| 05/30/2019 | Retrophin, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $2.33 | General |
| Category: Kidney Stones | ||||||
| 05/30/2019 | Retrophin, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $1.31 | General |
| Category: Kidney Stones | ||||||
| 05/30/2019 | Retrophin, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $0.54 | General |
| Category: Kidney Stones | ||||||
| 05/10/2019 | Lundbeck LLC | NORTHERA (Drug) | Travel and Lodging | Cash or cash equivalent | $455.60 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 3,464 | 22,368 | $1.7M | $501,534 |
| 2022 | 63 | 3,652 | 27,298 | $1.7M | $515,373 |
| 2021 | 58 | 4,135 | 10,949 | $2.0M | $579,044 |
| 2020 | 60 | 3,722 | 38,052 | $1.9M | $500,674 |
Total Patients
14,973
Total Services
98,667
Medicare Billing
$2.1M
Procedure Codes
238
All Medicare Procedures & Services
238 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 511 | 1,138 | $399,438 | $102,568 | 25.7% |
| G0277 | Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval | Office | 2023 | 19 | 737 | $258,687 | $98,183 | 38.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 67 | 198 | $182,409 | $53,826 | 29.5% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 20 | 131 | $101,263 | $29,141 | 28.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 1,320 | $79,080 | $24,253 | 30.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 363 | $85,668 | $22,148 | 25.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 155 | 155 | $58,280 | $19,646 | 33.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 54 | 81 | $62,775 | $18,555 | 29.6% |
| 99183 | Management of oxygen chamber therapy | Office | 2023 | 19 | 187 | $66,759 | $15,289 | 22.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 14 | 12,750 | $38,250 | $11,233 | 29.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 13 | 1,686 | $47,736 | $10,101 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 70 | $32,900 | $9,071 | 27.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 66 | $43,230 | $8,673 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $40,810 | $7,897 | 19.4% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 40 | 40 | $13,160 | $5,720 | 43.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 60 | $20,220 | $5,562 | 27.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 314 | 647 | $9,359 | $4,724 | 50.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 58 | 90 | $20,610 | $4,394 | 21.3% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 92 | 105 | $10,920 | $4,247 | 38.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 54 | 56 | $8,848 | $4,015 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $15,984 | $3,599 | 22.5% |
| 82306 | Vitamin d-3 level | Office | 2023 | 104 | 122 | $9,150 | $3,539 | 38.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 12 | 12 | $7,767 | $3,380 | 43.5% |
| 80069 | Kidney function blood test panel | Office | 2023 | 228 | 374 | $8,228 | $3,139 | 38.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 12 | 14 | $10,444 | $3,032 | 29.0% |
About Dr. Michael Feldman, M.D
Dr. Michael Feldman, M.D is a Nephrology healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184618761.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Feldman, M.D has received a total of $72,984 in payments from pharmaceutical and medical device companies, with $24.50 received in 2024. These payments were reported across 135 transactions from 14 companies. The most common payment nature is "Honoraria" ($52,600).
As a Medicare-enrolled provider, Feldman has provided services to 14,973 Medicare beneficiaries, totaling 98,667 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 238 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Bend, OR
- Active Since 09/09/2005
- Last Updated 01/29/2021
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1184618761
Products in Payments
- NORTHERA (Drug) $71,597
- BioPharma Sol - Research Devel (Biological) $300.00
- Fluid Systems - Research Devel (Biological) $300.00
- Renal - Non Product Related (Biological) $300.00
- WATCHMAN (Device) $141.51
- Veltassa (Drug) $79.39
- KRYSTEXXA (Biological) $37.01
- SOLIRIS (Drug) $17.14
- JYNARQUE (Drug) $16.53
- Victoza (Drug) $15.87
- TRULICITY (Drug) $15.56
- TARPEYO (Drug) $13.60
- Thiola (Drug) $11.46
- (815) Thiola (Drug) $4.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.